New concepts and insights into the role of radiation therapy in extracranial metastatic disease

Expert Review of Anticancer Therapy

Volumn 13, Issue 10, 2013, Pages 1145-1155

  Ricardi, Umberto ^a   Filippi, Andrea Riccardo ^a   Franco, Pierfrancesco ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b Ospedale Regionale U Parini   (Italy)

Author keywords

biology of metastases; extracranial metastases; oligometastases; radiosurgery; stereotactic ablative radiotherapy

Indexed keywords

CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; NARCOTIC ANALGESIC AGENT;

ADRENAL METASTASIS; BONE METASTASIS; CANCER CONTROL; CANCER GROWTH; CANCER LOCALIZATION; CANCER PAIN; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; COLORECTAL CANCER; EGFR GENE; GENE MUTATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; METASTASIS; OVERALL SURVIVAL; PILOT STUDY; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RADIOFREQUENCY ABLATION; RECTUM CANCER; REVIEW; STEREOTACTIC ABLATIVE RADIOTHERAPY; STOMACH CANCER;

HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PROGNOSIS; RADIOSURGERY;

EID: 84886412136     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2013.846829     Document Type: Review

References (70)

1. Hellman S, Weichselbaum RR. Oligometastases. J. Clin. Oncol. 13, 8-10 (1995).
2. Hellman S. Natural history of small breast cancers. J. Clin. Oncol. 12, 2229-2234 (1994).
3. Ksienski D, Woods R, Speers C et al. Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC). Ann. Surg. Oncol. 17, 3085-3093 (2010).
4. Lo SS, Fakiris AJ, Teh BS et al. Stereotactic body radiation therapy for oligometastases. Expert Rev. Anticancer Ther. 9(5), 621-635 (2009).
5. Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M. Review and uses of stereotactic body radiation therapy in oligometastases. Oncologist 17(8), 1100-1107 (2012).
6. Tree AC, Khoo VS, Eeles RA et al. Stereotactic body radiation therapy for oligometastases. Lancet Oncol. 14, e28-e37 (2013).
7. Niibe I, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn. J. Clin. Oncol. 40(2), 107-111 (2010).
8. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J. Clin. Oncol. 31, 1-8 (2013).
9. Fuks Z, Kolesnik R. Engaging the vascular component of the tumour response. Cancer Cell 8, 89-91 (2005).
10. Chmura SJ, Nodzenski E, Kharbanda S et al. Down-regulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. Mol. Pharmacol. 57, 792-796 (2000).
11. Moeller BJ, Dreher MR, Rabbani ZN et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8(2), 99-110 (2005).
12. Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumour immunotherapy. J. Exp. Med. 203(5), 1259-1271 (2006).
13. Lee Y, Auh SL, Wang Y et al. Therapeutic effects of ablative radiation on local tumour require CD8 T cells: changing strategies for cancer treatment. Blood 114(3), 589-595 (2009).
14. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumours increases the generation of tumour antigen-specific effector cells that traffic to the tumour. J. Immunol. 174(12), 7516-7523 (2005).
15. Demaria S, Kawashima N, Yang AM et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11(2), 728-734 (2005).
16. Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366(10), 925-931 (2013).
17. McCammon R, Schefter TE, Gaspar LE et al. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 73(1), 112-118 (2009).
18. Zelefsky M, Greco C, Motzer R et al. Tumour control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 82(5), 1744-1748 (2012).
19. Stinauer MA, Kavanagh BD, Schefter TE et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat. Oncol. 6, 34 (2011).
20. Wulf J, Hadinger U, Oppitz U, Thiele W, Ness-Dourdomas R, Flentje M. Stereotactic radiotherapy of targets in the lung and liver. Stahlenther. Onkol. 177, 645-655 (2001).
21. Onimaru R, Shirato H, Shimizu S et al. Tolerance of organs at risk in small volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int. J. Radiat. Oncol. Biol. Phys. 56, 126-135 (2003).
22. Yoon SM, Choi EK, Lee SW et al. Clinical results of stereotactic body frame based fractionated radiation therapy for primary or metastatic thoracic tumours. Acta Oncol. 45, 1108-1114 (2006).
23. Okunieff P, Petersen AL, Philip A et al. Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol. 45, 808-817 (2006).
24. Norihisa Y, Nagata Y, Takayama K et al. Stereotactic body radiotherapy for oligometastatic lung tumours. Int. J. Radiat. Oncol. Biol. Phys. 72(2), 398-403 (2008).
25. Brown WT, Wu X, Fowler JF et al. Lung metastases treated by CyberKnife image-guided robotic stereotactic radiosurgery at 41 months. South. Med. J. 101, 376-382 (2008).
26. Rusthoven KE, Kavanagh BD, Burri SH et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J. Clin. Oncol. 27, 1579-1584 (2009).
27. Ricardi U, Filippi AR, Guarneri A et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer 75(1), 77-81 (2012).
28. Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int. J. Radiat. Oncol. Biol. Phys. 60, 186-196 (2004).
29. Filippi AR, Badellino S, Guarneri A et al. Outcomes of single fraction stereotactic ablative radiotherapy in lung metastases. Technol. Cancer Res. Treat. doi:10.7785/tcrt.2012.500355 (2013) (Epub ahead of print).
30. Greco C, Zelefsky MJ, Lovelock M et al. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int. J. Radiat. Oncol. Biol. Phys. 79(4), 1151-1157 (2011).
31. Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J. Thorac Oncol. 5(7), 1091-1099 (2010).
32. Pastorino U, Buyse M, Friedel G et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J. Thorac Cardiovasc. Surg. 113(1), 37-47 (1997).
33. Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJ, Langendijk JA. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy? Radiother. Oncol. 107(3), 409-413 (2013).
34. Chawla S, Chen Y, Katz AW et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int. J. Radiat. Oncol. Biol. Phys. 75(1), 71-75 (2009).
35. Holy R, Piroth M, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther. Onkol. 187, 245-251 (2011).
36. Torok J, Wegner RE, Burton SA, Heron DE. Stereotactic body radiation therapy for adrenal metastases: a retrospective review of noninvasive therapeutic strategy. Future Oncol. 7(1), 151-166 (2011).
37. Casamassima F, Livi L, Masciullo S et al. Stereotactic radiotherapy for adrenal gland metastases: University of Florence experience. Int. J. Radiat. Oncol. Biol. Phys. 82(2), 919-923 (2012).
38. Scorsetti M, Alongi F, Filippi AR et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol. 51(5), 618-623 (2012).
39. Herfarth KK, Hof H, Bahner ML et al. Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumours. Int. J. Radiat. Oncol. Biol. Phys. 57, 444-451 (2003).
40. Hoyer M, Roed H, Traberg Hansen A et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 45, 823-830 (2006).
41. Kavanagh BD, Schefter TE, Cardenes HR et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 45, 848-855 (2006).
42. Mendez-Romero A, Wunderink W, Hussain SM et al. Stereotactic body radiation therapy for primary and metastatic liver tumours. Acta Oncol. 45, 831-837 (2006).
43. Lee MT, Kim JJ, Dinninwell R et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J. Clin. Oncol. 27, 1585-1591 (2009).
44. Rusthoven KE, Kavanagh BD, Cardenes H et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J. Clin. Oncol. 27, 1572-1578 (2009).
45. Goodman KA, Wiegner EA, Maturen KE et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int. J. Radiat. Oncol. Biol. Phys. 78, 486-493 (2010).
46. Rule W, Timmerman R, Tong L et al. Phase I dose escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann. Surg. Oncol. 18(4), 1081-1087 (2011).
47. Scorsetti M, Arcangeli S, Tozzi A et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int. J. Radiat. Oncol. Biol. Phys. 86(2), 336-342 (2013).
48. Choi C, Cho C, Yoo S et al. Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int. J. Radiat.Oncol. Biol. Phys. 74, 147-153 (2009).
49. Jereczek-Fossa BA, Fariselli L, Beltramo G et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother. Oncol. 93(1), 14-17 (2009).
50. Kim MS, Yoo SY, Cho CK et al. Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer. J. Korean Med. Sci. 24, 488-492 (2009).
51. Kim MS, Cho CK, Yang KM, Lee DH, Moon SM, Shin YJ. Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence form colorectal cancer. World J. Gastroenterol. 15, 6091-6095 (2009).
52. Casamassima F, Masi L, Menichelli C et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 97, 49-55 (2011).
53. Bignardi M, Cozzi L, Fogliata A et al. Critical appraisal of volumetric modulated arc therapy in stereotactic body radiation therapy for metastases to abdominal lymph nodes. Int. J. Radiat. Oncol. Biol. Phys. 75(5), 1570-1577 (2009).
54. Ryu S, Fang Yin F, Rock J et al. Image-guided and intensity-modulated radiosurgery for patients with spinal metastasis. Cancer 97, 2013-2018 (2003).
55. Chang EL, Shiu AS, Mendel E et al. Phase I/II study of stereotactic body radiotherapy for spinal metastases and its pattern of failure. J. Neurosurg. Spine 7, 151-160 (2007).
56. Gibbs IC, Kamnerdsupaphon P, Ryu MR et al. Image-guided robotic radiosurgery for spinal metastases. Radiother. Oncol. 82, 185-190 (2007).
57. Gerszten PC, Burton SA, Ozhasoglu C et al. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine 32, 193-199 (2007).
58. Yamada Y, Bilsky MH, Lovelock DM et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int. J. Radiat. Oncol. Biol. Phys. 71, 484-490 (2008).
59. Tsai JT, Lin JW, Chiu WT et al. Assessment of image-guided CyberKnife radiosurgery for metastatic spine tumours. J. Neuroncol. 94, 119-127 (2009).
60. Nguyen QN, Shiu AS, Rhines LD et al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 76, 1185-1192 (2010).
61. Milano MT, Katz AW, Muhs AG et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 112(3), 650-658 (2007).
62. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int. J. Radiat. Oncol. Biol. Phys. 83(3), 878-886 (2011).
63. Salama JK, Hassella MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases. Cancer 118(11), 2962-2970 (2011).
64. De Ruysscher D, Wanders R, van Baardwijk A et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases. Long term results of a prospective phase II trial (Nct01282450). J. Thorac Oncol. 7(10), 1547-1555 (2012).
65. Weickhardt AJ, Scheier B, Malachy Burke J et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J. Thorac Oncol. 7(12), 1807-1814 (2012).
66. Yu H, Sima CS, Huang J et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J. Thorac Oncol. 8(3), 346-351 (2103).
67. Milano MT, Katz AW, Okunieff P et al. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am. J. Clin. Oncol. 33, 157-163 (2010).
68. Singh D, Yi WS, Brasacchio RA et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int. J. Radiat. Oncol. Biol. Phys. 58(1), 3-10 (2004).
69. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 8(6), 378-382 (2011).
70. Metha N, Mauer AM, Hellman S et al. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int. J. Oncol. 25, 1677-1683 (2004).